SCHEMBL21816567

SCHEMBL21816567

CCCCc1ccc(-c2ccc(O)cc2)nc1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 10/20 0.88
▸ SMN1; SMN2 Q16637 10/20 0.88
▸ NPC1 O15118 9/20 0.88
▸ MAPT P10636 4/20 0.88
▸ STAT3 P40763 1/20 0.88
▸ ATM Q13315 1/20 0.88
▸ NFKB1 P19838 5/20 0.72
▸ NFKB2 Q00653 4/20 0.72
▸ RELA Q04206 4/20 0.72
▸ L3MBTL1 Q9Y468 3/20 0.72
▸ MAPK1 P28482 2/20 0.72
▸ CASP3 P42574 2/20 0.62
▸ SENP8 Q96LD8 2/20 0.62
▸ SENP7 Q9BQF6 2/20 0.62
▸ SENP6 Q9GZR1 2/20 0.62
▸ TP53 P04637 3/20 0.57
▸ POLB P06746 1/20 0.57
▸ KDM4E B2RXH2 5/20 0.56
▸ ALDH1A1 P00352 5/20 0.56
▸ HPGD P15428 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9329063 0.98 RAB9A (0.86) RAB9ASMN1; SMN2NPC1MAPTSTAT3
SCHEMBL10459672 0.95 RAB9A (0.97) RAB9ASMN1; SMN2NPC1MAPTSTAT3
SCHEMBL9180479 0.94 RAB9A (1.00) RAB9ASMN1; SMN2NPC1MAPTSTAT3
SCHEMBL10685934 0.94 RAB9A (1.00) RAB9ASMN1; SMN2NPC1MAPTSTAT3
SCHEMBL7789917 0.94 RAB9A (0.94) RAB9ASMN1; SMN2NPC1MAPTSTAT3
SCHEMBL7752727 0.94 RAB9A (1.00) RAB9ASMN1; SMN2NPC1MAPTSTAT3
SCHEMBL8025073 0.94 RAB9A (1.00) RAB9ASMN1; SMN2NPC1MAPTSTAT3
SCHEMBL6283948 0.94 RAB9A (1.00) RAB9ASMN1; SMN2NPC1MAPTSTAT3
SCHEMBL9326045 0.92 RAB9A (0.97) RAB9ASMN1; SMN2NPC1MAPTSTAT3
SCHEMBL9326013 0.92 RAB9A (0.97) RAB9ASMN1; SMN2NPC1MAPTSTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240389588-A1 COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2024-11-28 — — US disclosed
US-12022832-B2 Compounds and methods for treating nematode infections THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2024-07-02 — — US disclosed
US-12022832-B2 Compounds and methods for treating nematode infections THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2024-07-02 — — US disclosed
US-12022832-B2 Compounds and methods for treating nematode infections THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2024-07-02 — — US disclosed
US-20220354117-A1 COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2022-11-10 — — US disclosed
WO-2020051689-A1 COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2020-03-19 — — WO disclosed
WO-2020051689-A1 COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2020-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12022832-B2 Compounds and methods for treating nematode infections HNMT, NISCH, HRH2 RAB9A 2708/4885SMN1; SMN2 1819/4885NPC1 385/4885
US-20220354117-A1 COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS HNMT, NISCH, HRH2 RAB9A 2708/4885SMN1; SMN2 1819/4885NPC1 385/4885
US-20240389588-A1 COMPOUNDS AND METHODS FOR TREATING NEMATODE INFECTIONS HNMT, NISCH, HRH2 RAB9A 2708/4885SMN1; SMN2 1819/4885NPC1 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback